Cutaneous nontuberculous mycobacterial infection in Thailand

A 7-year retrospective review

Phatcharawat Chirasuthat, MD, Korn Triyangkulsri, MD, Suthinee Rutnin, MD, Kumutnart Chanprapaph, MD, Vasanop Vachiramon, MD∗

Abstract
A remarkable increase in the prevalence of cutaneous nontuberculous mycobacterial (NTM) infection has occurred worldwide. However, updated data regarding cutaneous NTM infection in Thailand is limited.

This study aims to describe the clinical manifestations, pathogenic organism, and prognostic factors of cutaneous NTM infections among patients living in Thailand.

The electronic medical records of all patients with confirmatory diagnosis of cutaneous NTM infection from either positive cultures or polymerase chain reaction were retrospectively reviewed at a university-based hospital.

From 2011 to 2017, a total of 88 patients with a confirmed diagnosis of cutaneous NTM infection were included. Mycobacterium abscessus was the most common pathogens followed by M haemophilum and M marinum (61.4%, 10.2%, and 8.1%, respectively). Nodule and plaque were 2 most common lesions (26.4% and 25.5%, respectively) and lower leg is the most common site of involvement (50.9%). The majority of patients presented with single lesion (67%). Seven patients (7.9%) had history of surgical procedure and/or cosmetic injection before the development of lesion and all pathogenic organisms in this group were rapidly growing mycobacteria. Sweet’s syndrome and erythema nodosum were the 2 most common reactive dermatoses, presented in 3.4% and 2.3%, respectively. The majority of patients infected with cutaneous M haemophilum infections were immunocompromised and lacked history of preceding trauma (77.8%). Patients with cutaneous NTM that receiving less than 3 medications was associated with higher disease relapse (odds ratio 65.86; P= .02).

M abscessus is the most common pathogen of cutaneous NTM infection in Thailand. The prevalence of M haemophilum is increasing and should be particularly cautious in immunocompromised patients. Rapidly growing mycobacteria should be suspected in all cases of procedure-related cutaneous NTM. We recommend at least 3 antibiotics should be considered for cutaneous NTM infection to reduce the rate of relapse.

Abbreviations: HIV = human immunodeficiency virus, NTM = nontuberculous mycobacteria, PCR = polymerase chain reaction.

Keywords: granuloma, injectable, Mycobacterium abscessus, Mycobacterium haemophilum, surgery

1. Introduction

The nontuberculous mycobacteria (NTM) are free-living, non-motile, acid-fast bacilli that can be present in numerous environmental sources including water, soil, food products, and domestic and wild animals.[3] The NTM pathogens were first classified by Runyon in 1954 based upon the rate of growth in vitro and pigment production following exposure to light.[2] Due to advances in identification utilizing genomic analysis, more than 170 species of mycobacteria have been identified.[1] NTM pathogens compose a diverse group of environmental organisms that can produce clinical disease in any body tissue, including the skin and soft tissue. NTM can cause a broad range of infections that vary depending on the particular NTM species and the host immunity. There are 6 major clinical syndromes caused by NTM infection;

1. pulmonary infection,
2. disseminated infection,
3. local nontender lymphadenitis,
4. chronic granulomatous infections of bursae, joints, tendon sheaths, and bones,
5. catheter-related infections,
6. skin and soft-tissue infections.[4]

The incidence of cutaneous nontuberculous mycobacterial infections has increased dramatically during the past several years due to numerous factors including the increase application of immunosuppressive therapies and more frequent use of surgical and cosmetic procedures. In addition, vast improvement in the detection of NTM via cultures and polymerase chain reaction...
Almost all NTM species have been incriminated in cutaneous disease. The most common species in the United States and Europe are *Mycobacterium marinum* and the rapidly growing mycobacteria. A drastic shift of mycobacterium species was observed in many countries from previous reports.9–11 The latest reviews on cutaneous NTM infection in Thailand dated back almost 2 decades ago from 1994 to 2001.9–11 In this study, we aimed to describe the clinical manifestations, pathogenic organisms, and prognostic factors for cutaneous NTM infection in Thailand between 2012 and 2018.

2. Methods

2.1. Data collection

The electronic medical records of patients with cutaneous NTM infections who visited a university-based hospital in Bangkok, Thailand (Ramathibodi Hospital, Mahidol University, Bangkok, Thailand) between January 2012 and December 2018 were retrospectively reviewed. The study was approved by institutional review board for human research (protocol number 11-61-29).

The diagnosis of cutaneous NTM was confirmed by histopathology and microbiologic study. Histopathologic evaluation consisted of the routine process of tissue staining consisting of hematoxylin-eosin and Ziehl-Neelsen in cases suspected of cutaneous NTM infections. Most tissue samples were processed according to the standard methods for mycobacterial culture including blood agar, Löwenstein-Jensen agar, and BD MGIT Mycobacteria Growth Indicator Tube (Becton, Dickinson U.K. Limited, Berkshire, UK). All culture specimens were incubated at 37°C and 30°C to detect *M. haemophilum* and *M. marinum* infections. Culture isolates were detected to the species level using partial sequencing of the 16S rRNA gene. PCR for mycobacterial results were identified by AnyplexMTB/NTM Real-time Detection (Seegene Inc., Seoul, Korea). Clinical, epidemiological, and microbiological data were collected.

Patients who had compatible cutaneous lesion and histopathologic findings consistent with cutaneous NTM infection and positive microbiologic evidences (positive cultures and/or PCR results) were included in this study.

2.2. Statistical analysis

A Chi-squared test was used to compare differences in categorical data while continuous variables were compared by an independent *t* test. A *P*-value of <.05 was considered statistically significant. All analyses were performed using the computer software (STATA/SE version 14.1, STATA Corp LLC, College station, TX).

3. Results

During the 7-year study period, 149 patients with the presumed diagnosis of cutaneous NTM infections based on clinical and histopathology were identified. A total of 88 patients (female 66, male 22) who had positive PCR and/or culture for NTM infection were included in this study. The median age of patients was 51 years (range 2–90). The median time from the onset of symptom to the diagnosis of NTM was 4 weeks (1–136 weeks). Twenty-four of 88 patients (27.3%) were immunocompromised while 64 were immunocompetent host. Insulin-independent diabetes mellitus, post-organ transplantation treated with immunosuppressive drugs, and malignancy were found in 9 (10.2%), 8 (9.1%), and 7 (8.0%) patients respectively. There were 3 patients with adult-onset immunodeficiency. None of our patients had human immunodeficiency virus (HIV) infection. Of 8 patients with post-organ transplantation, 5 had *M. haemophilum* infection. Data on the clinical characteristic is demonstrated in Table 1.

Of 88 patients who had positive tissue cultures and/or PCR for NTM, 84 had identifiable pathogenic species while in the remaining 4 the organism was unidentifiable. Among 84 patients with detectable NTM species, the most common pathogen was *M. abscessus* (54 cases; 61.4%), followed by *M. haemophilum*, *M. marinum*, and *M. fortuitum* which were positive in 9 (10.2%), 7 (8.1%), and 6 (6.8%) cases, respectively. Tissue imprint for

### Table 1

| Variables                                  | Result |
|--------------------------------------------|--------|
| Selected by Anyplex MTB/NTM real-time detection to detect *M. haemophilum* and *M. marinum* infections. Culture isolates were detected to the species level using partial sequencing of the 16S rRNA gene. PCR for mycobacterial results were identified by Anyplex MTB/NTM Real-time Detection (Seegene Inc., Seoul, Korea). Clinical, epidemiological, and microbiological data were collected. Patients who had compatible cutaneous lesion and histopathologic findings consistent with cutaneous NTM infection and positive microbiologic evidences (positive cultures and/or PCR results) were included in this study. A Chi-squared test was used to compare differences in categorical data while continuous variables were compared by an independent *t* test. A *P*-value of <.05 was considered statistically significant. All analyses were performed using the computer software (STATA/SE version 14.1, STATA Corp LLC, College station, TX).

### 3. Results

During the 7-year study period, 149 patients with the presumed diagnosis of cutaneous NTM infections based on clinical and histopathology were identified. A total of 88 patients (female 66, male 22) who had positive PCR and/or culture for NTM infection were included in this study. The median age of patients was 51 years (range 2–90). The median time from the onset of symptom to the diagnosis of NTM was 4 weeks (1–136 weeks). Twenty-four of 88 patients (27.3%) were immunocompromised while 64 were immunocompetent host. Insulin-independent diabetes mellitus, post-organ transplantation treated with immunosuppressive drugs, and malignancy were found in 9 (10.2%), 8 (9.1%), and 7 (8.0%) patients respectively. There were 3 patients with adult-onset immunodeficiency. None of our patients had human immunodeficiency virus (HIV) infection. Of 8 patients with post-organ transplantation, 5 had *M. haemophilum* infection. Data on the clinical characteristic is demonstrated in Table 1.

Of 88 patients who had positive tissue cultures and/or PCR for NTM, 84 had identifiable pathogenic species while in the remaining 4 the organism was unidentifiable. Among 84 patients with detectable NTM species, the most common pathogen was *M. abscessus* (54 cases; 61.4%), followed by *M. haemophilum*, *M. marinum*, and *M. fortuitum* which were positive in 9 (10.2%), 7 (8.1%), and 6 (6.8%) cases, respectively. Tissue imprint for

### Table 1

| Variables | Result |
|-----------|--------|
| Median age at diagnosis, yr (ranges) | 51 (2–90) |
| Gender (n=88) | Female 66 (75%), Male 22 (25%) |
| Immune compromised hosts (n=24) | Diabetes mellitus 9 (10.2%), Post-organ transplantations 8 (9.1%), Malignancy 7 (8%), Adult-onset immune deficiency syndrome 3 (3.4%), Autoimmune diseases 2 (2.3%) |
| Number of lesions (n=88) | Single 59 (67%), 2 lesions 13 (14.8%), 3 lesions 7 (7.9%), 4 lesions 2 (2.3%), ≥5 lesions 7 (7.9%) |
| Morphology (n=110) | Nodule 29 (26.4%), Plaque 28 (25.5%), Papule 18 (16.4%), Abscess 14 (12.7%), Patch 7 (6.3%), Pustule 6 (5.5%), Ulcer 5 (4.5%), Cellulitis-liked lesions 2 (1.8%), Sporotrichoid lesions 1 (0.9%) |

|= Some patients had more than 1 underlying diseases. |
| † | Some patients had more than 1 lesions. |
| ‡ | Some patients had more than 1 sites of involvement. |
Acid-fast bacilli staining was positive in 15 out of 54 patients (27.8%) and Acid-fast bacilli staining from histopathology was positive in 8 of 42 patients (19%).

Traumatic injury to the skin was identified in 24 out of 88 patients (27.3%). This includes aquatic-related injury, insect bite, wood splinter injury, and procedure-related injury. All procedures-related NTM infection were linked to rapidly growing pathogens. Two patients had a history of cosmetic injection by unlicensed providers (filler injection and mesotherapy for fat reduction). Both of them suffered from *M. abscessus* infection (Table 1). A total of 9 patients had *M. haemophilum* infections which occurred without history of skin trauma. Seven out of 9 were immunocompromised patients (77.8%).

Fifty-nine patients (67%) with cutaneous NTM infection presented with single lesion whereas multiple skin lesions occurred in 29 cases (33%). Nodules and plaques were 2 most common skin lesions in cutaneous NTM infection (26.4% and 25.5%, respectively). Other presentations included papules (16.4%), abscesses (12.7%), patches (6.4%), pustules (5.4%), ulcers (4.5%), cellulitis-like lesions (1.8%), or sporotrichoid lesions (0.9%) (Table 1). Clinical morphology in association to the pathogenic organisms is demonstrated in Table 2. The most commonly involved sites were legs 50.9%, followed by forearm (15.8%), trunk (10.2%), and face (8.3%) (Figs. 1 and 2).

Associated symptoms (eg, fever, weight loss, lymphadenopathy, etc) were found in 15 patients (17%). Extra-cutaneous involvement of cutaneous NTM infections was found in 6 cases, of which, pulmonary involvement occurred in 3 patients. Other affected organs were hematologic (blood, lymph node), eye, sinus, or bone and joint. Reactive dermatoses were found in 6 out of 88 patients (6.8%). Sweet syndrome and erythema nodosum were the 2 most common reactive dermatoses presented in 3 (3.4%) and 2 (2.3%) patients, respectively. They could be found before, concurrent, or after NTM infections.

With regards to treatment, 81 patients were treated at our institute while 7 patients were treated elsewhere. All 81 patients received medical treatments and 58 patients commenced ≥3 medications. Thirty-four patients had surgical excision together with oral medication. The most commonly-prescribed regimen was combination of clarithromycin, ciprofloxacin, and doxycycline. The mean time to cutaneous remission was 40 (±2) weeks. Among 81 patients, 79 patients achieved clinical remission and 2 patients lost to follow-up.

Relapse was defined by the development of cutaneous lesions within 6 months after clinical remission with histological and microbiological confirmation. After achieving cutaneous remission, 74 patients remained on continuous follow-up for a duration of at least 6 months. Among these, 7 patients had relapse. A summary of treatment and outcome is shown in Table 3.

Subgroup analysis on immunocompromised patients showed that the most common organism in this group was *M. abscessus* which comprised of 41.7% of immunocompromised subjects, followed by *M. haemophilum* (29.2%). A higher prevalence of extracutaneous involvement (20.8% vs 1.6%, *P* < .01), reactive dermatoses (20.8% vs 1.6%, *P* < .01), and relapse (20.8% vs 6.3%, *P* = .044) were observed in immunocompromised compared to immunocompetent hosts (Table 4).

Regarding factors associated with prognosis, there was no clinical or laboratory parameters associated with treatment

---

**Table 2**

Comparison of clinical morphology according to pathogenic organisms.

| Organisms    | Nodule | Plaque | Abscess | Papule | Patch | Cellulitis | Sporotrichoid | Others |
|--------------|--------|--------|---------|--------|-------|------------|---------------|--------|
| *M. abscessus* | 26.9   | 21.8   | 15.4    | 15.4   | 5.1   | 1.3        | 1.3           | 12.8   |
| *M. haemophilum* | 16.7   | 33.3   | 25      | 16.7   | 8.3   | –          | 8.3           | –      |
| *M. marinum*    | 20.0   | 30.0   | 10      | 10.0   | 10.0  | 10.0       | 10.0          | –      |
| *M. fortuitum*  | 14.3   | 14.3   | 28.6    | 14.3   | –     | –          | –             | 28.5   |

---

Figure 1. A 63 yr-old healthy man with cutaneous *Mycobacterium abscessus* infection. He had history of insect bite before the development of lesion.

Figure 2. A 59 yr-old man with hypertension, diabetes, S/P kidney transplant with papulopustular lesions, ulcerated nodules, and abscesses on both feet. Tissue culture and PCR revealed *Mycobacterium haemophilum*. PCR = polymerase chain reaction.
response except for disease relapse that occurred to those who received less than 3 medications (Adjusted odds ratio 65.86; 95% confidence interval 2.02–2.147.18; P = .02) (Table 5).

4. Discussion

Several studies have demonstrated that the rate of NTM species isolation is rapidly increasing worldwide[16–11]. Likewise, cutaneous NTM infection has significantly increased over the past 30 years.[12,13] Most studies reported M. marinum as the most common pathogenic organism.[14,15] However, some studies identified rapidly growing mycobacteria as the predominant causative species.[16,17] In our study, M. abscessus is the most common organism causing cutaneous NTM infection. This finding is similar to a study by Mahaisavariya et al which reviewed 40 cases of NTM in Thailand during 1994 to 2001. The predominant organism was rapidly growing mycobacteria responsible for 65% of cases, followed by M. marinum (30%).[18,19] Our study was conducted at a university-based hospital in Bangkok metropolitan area and located nowhere near rivers, lakes, and so on. which may a contributing factor to why M. marinum was not the most prevalent organism.

M. haemophilum was the second most common pathogens identified in our study (10.2%). This finding was not consistent with previous reports.[18–11] This could be explained by the fact that many of our patients were immunocompromised host which might predisposing to this infection Moreover, our laboratory routinely performs a special culture for causative species.[16,17] In our study, M. abscessus is the most common pathogenic organisms.[5,14,15] However, some studies identified rapidly growing mycobacteria as the predominant pathogen that commonly presenting with cutaneous lesions in immunocompromised patients.[18–22] The impairment of cell-mediated immunity appears to play a role in the pathogenesis of M. haemophilum infection. Restoration of cell-mediated immune function during the course of a patient’s illness also appears to facilitate the recovery.[13] According to a laboratory study in murine models, albino mice with corticosteroids-induced immunosuppression, unlike the immunocompetent mice, developed cutaneous disease after being injected with M. haemophilum.[24] In addition, we also observed a higher relapse rate in M. haemophilum infection (44.4%) than non-haemophilum mycobacterial infection (6.3%) which might be from the significantly higher number of immunocompromised patients in our study that may determine poorer treatment outcome.

Immunosuppression is a well-known risk factor for cutaneous NTM infections. Immunocompromised patients from our study consisted of insulin-independent diabetes mellitus, post-organ transplantation treated with immunosuppressive drugs, and malignancy. However, none of our patients had HIV infection. Interestingly, we found 3 cases of adult-onset immune deficiency syndrome without cutaneous NTM infections. Immunocompromised patients from our study consisted of insulin-independent diabetes mellitus, post-organ transplantation treated with immunosuppressive drugs, and malignancy. However, none of our patients had HIV infection. Interestingly, we found 3 cases of adult-onset immune deficiency syndrome without cutaneous NTM infections. Adult onset immune deficiency, an emerging disease in East Asia particularly in Thailand, results in the production of circulating of antiinterferon-gamma antibody.[18,19] It is recognized as an acquired immunodeficiency syndrome-like illness in HIV seronegative patients and occurring in otherwise immunocompetent adults.[20–23] This finding emphasizes the importance of immune status evaluation in patient who had cutaneous NTM infection.

Skin trauma is another risk factor for cutaneous NTM infections. In the present study, 24 patients (27.3%) had preceding skin injuries and all of them were caused by rapidly growing mycobacteria. The type of skin injury identified in our patients includes wood splinter-related injury, aquatic-related injury, cosmetic procedure, and mosquito bite. In procedure-related infections, the causative organisms were all from rapidly growing mycobacteria, a finding similar to previous case report and series.[25–27] Apart from post-operative cutaneous NTM infection, cosmetic procedures, such as filler injection, or mesotherapy may contribute to an increase incidence of NTM infections, which has been confirmed by many authors in recent years.[26–28] As our data included procedure-related NTM infections accounting for 7.9% of the study population, the

### Table 3

| Medications                | (n=61) | 70 (86.4%) | 57 (70.4%) | 41 (50.6%) | 10 (12.3%) | 8 (9.9%) | 58 (71.6%) | 34 patients | 40 (9.5%) |
|---------------------------|--------|------------|------------|------------|------------|----------|------------|-------------|-----------|

*Other medications included azithromycin 7 (8.6%), trimethoprim/sulfamethoxazole 6 (7.4%), ethambutol 1 (6.2%), levofloxacin 5 (6.2%), imipenem 5 (6.2%), isoniazid 3 (3.7%), amoxicillin clavulinate 2 (2.5%).

### Table 4

**Comparison of cutaneous nontuberculous mycobacterial infection features by immune status.**

| Characteristics         | Immunocompetent, n (%) | Immunocompromised, n (%) | P-value |
|-------------------------|-----------------------|--------------------------|---------|
| Age at diagnosis (yr), mean (+/- SD) | 47.97 (+/- 20.05) | 40.19 (+/- 20.38) | .44     |
| Gender: female/male     | 53/11                 | 13/11                    | .006    |
| Previous history of trauma | 21/37 (56.8%) | 3/5 (53.7%) | .222    |
| Extra-cutaneous involvement | 1/64 (1.6%) | 5/24 (20.8%) | .005    |
| Reactive dermatoses     | 1/64 (1.6%) | 5/24 (20.8%) | .005    |
| Relapse                 | 4/64 (6.3%) | 5/21 (20.8%) | .044    |

### Table 5

**Factors associated with relapse.**

| Factors associated with relapse | Number of patients with relapse (%) | Adjusted OR (95% CI) | P-value |
|--------------------------------|-------------------------------------|----------------------|---------|
| Number of lesions              | 20.95 (0.98–447.54)                  | .05                  |
| ≤2 lesions (n=49)              | 2 (4.1%)                             |                      |         |
| ≥2 lesions (n=25)              | 5 (20%)                              |                      |         |
| Type of Mycobacteria           | 15.65 (0.82–300.28)                  | .07                  |
| -Slow growers (n=15)           | 4 (26.7%)                            |                      |         |
| -Rapid growers (n=56)          | 3 (5.4%)                             |                      |         |
| Number of medications          | 65.86 (2.02–1.147.18)                | .02                  |
| ≤3 medications (n=20)          | 5 (25%)                              |                      |         |
| ≥3 medications (n=48)          | 2 (4.2%)                             |                      |         |

* = confidence interval, OR = odds ratio.

† Unidentified organisms were excluded from analysis.

‡ Patients who were treated with only excision were excluded from analysis.
prevalence of *M. abscessus* may have been enhanced compared to previous reports. [5,14,15] We emphasize the importance of considering rapidly growing mycobacteria infection and administering empirical antimicrobial agents in cases suspicious of medical procedure-related cutaneous NTM. For mosquito bite and cutaneous NTM infection, there are previous vitro studies documenting that very low dose of *M. ulcersens* can penetrate through mosquito bite wound and is sufficient to cause buruli ulcer. [29,30] To date, there are still no report on the association between other mycobacterial organisms and cutaneous NTM infection. Further studies are required to prove this possibility.

Regarding cutaneous morphology, nodules and plaques were 2 most common skin lesions in cutaneous NTM infection (26.4% and 25.5%, respectively). Other presentations included abscesses, papules, patches, cellulitis-like lesions, and sporotrichoid lesions. Cellulitis-like lesions and sporotrichoid lesions were commonly caused by *M. marinum* and *M. abscessus* infections. As for other cutaneous mycobacterium infection, there may be some similarities in terms of cutaneous morphology. For example, nodules and plaques can be found in cutaneous tuberculosis as well as leprosy. In such cases, histopathologic examination and microbiologic study can help differentiate among them.

There are many studies documenting the association between NTM infections and reactive dermatoses such as Sweet syndrome, pustular eruptions, or erythema nodosum. [31–33] The correlation and pathogenesis is still unclear, but it is hypothesized that infections may trigger cytokine secretion composed of mainly interleukin 1 mediating the infiltration of neutrophils to the skin lesions. [34] In addition, immunosuppression may result in the compensatory hyperactivation of innate immune responses to combat intracellular infections. Furthermore, immune dysregulation of IL-23/Th17, similar to that of other cutaneous mycobacterium infection, may be responsible for recruitment, activation, and survival of neutrophils in the skin of these patients. [35] There seems to be a higher prevalence of reactive dermatoses in disseminated disease (53.8%) than in limited cutaneous form (6.8%). [22]

In terms of prognosis, patients that have received less than 3 medications were significantly associated with disease relapse in this study. Corresponding to the previous guideline and recommendations [11,36,37] we recommended the use of 3 antibiotics with at least 1 macrolide for the treatment of cutaneous NTM for at least 4 months duration to reduce the rate of relapse.

### Acknowledgments

The authors thank Dr. Poonkiet Suchonwanit for his help in preparing the photographs and Dr. Kunlawat Thadanipon for his help in statistical calculation.

### Author contributions

**Data curation:** Phatcharawat Chirasuthat, Korn Triyangkulri.

**Formal analysis:** Phatcharawat Chirasuthat, Korn Triyangkulri.

**Investigation:** Phatcharawat Chirasuthat, Vasanop Vachiramon.

**Resources:** Suthinee Rutnin, Vasanop Vachiramon.

**Writing – original draft:** Phatcharawat Chirasuthat.

**Writing – review & editing:** Kummunt Chanprapaph, Vasanop Vachiramon.

### References

[1] Griffith DE, Akcamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175:367–416.

[2] Timpe A, Runyon EH. The relationship of atypical acid-fast bacteria to human disease; a preliminary report. J Lab Clin Med 1954;44:202–9.

[3] McNabb A, Eisler D, Adar K, et al. Assessment of partial sequencing of the 65-kilodalton heat shock protein gene (hsp65) for routine identification of Mycobacterium species isolated from clinical sources. J Clin Microbiol 2004;42:3000–11.

[4] Penitjean G, Fluckiger U, Scharen S, et al. Vertebral osteomyelitis caused by non-tuberculous mycobacteria. Clin Microbiol Infect 2004;10:951–3.

[5] Wentworth AB, Drage LA, Wengenack NL, et al. Increased incidence of cutaneous nontuberculous mycobacterial infection, 1980 to 2009: a population-based study. Mayo Clin Proc 2013;88:38–45.

[6] Falkingham JO. The changing pattern of nontuberculous mycobacterial disease. Can J Infect Dis 2003;14:281–6.

[7] Mahasavariya P, Chaiprasert A, Khemngern S, et al. Nontuberculous mycobacterial skin infections: clinical and bacteriological studies. J Med Assoc Thai 2003;86:52–60.

[8] Yoo JW, Jo KW, Kim MN, et al. Increasing trend of isolation of non-tuberculous mycobacteria in a tertiary university hospital in South Korea. Tuberc Respir Dis (Seoul) 2012;72:409–15.

[9] Tsai CF, Shau MY, Chang YH, et al. Trends of mycobacterial clinical isolates in Taiwan. Trans R Soc Trop Med Hyg 2011;105:148–52.

[10] Chen HY, Chen CY, Huang CT, et al. Skin and soft-tissue infection caused by non-tuberculous mycobacteria in Taiwan, 1997–2008. Epidemiol Infect 2011;139:121–9.

[11] Lai CC, Tan CK, Chou CH, et al. Increasing incidence of nontuberculous mycobacteria, Taiwan, 2000–2008. Emerg Infect Dis 2010;16:294–6.

[12] Alcaide F, Esteban J. Cutaneous and soft skin infections due to non-tuberculous mycobacteria. Enferm Infect Microbiol Clin 2010;28(Suppl 1): 46–50.

[13] Khan FA, Khakoo R. Nontuberculous mycobacterial cutaneous infections: an updated review. Cuts 2011;88:194–200.

[14] Doduk-Gad R, Dyachenko P, Ziv M, et al. Nontuberculous mycobacterial infections of the skin: a retrospective study of 25 cases. J Am Acad Dermatol 2007;57:413–20.

[15] Alhabas O, Marrouch N, Kantar MM, et al. Cutaneous non-tuberculous Mycobacterial infections: a clinical and histopathological study of 17 cases from Lebanon. J Eur Acad Dermatol Venereol 2011;25:33–42.

[16] Liao CH, Lai CC, Ding LW, et al. Skin and soft tissue infection caused by non-tuberculous mycobacteria. Int J Tuberc Lung Dis 2007;11:96–102.

[17] Escolonilla P, Esteban J, Soriano ML, et al. Cutaneous manifestations of infection by nontuberculous mycobacteria. Clin Exp Dermatol 1998;23:214–21.

[18] Doffinger R, Helbert MR, Barcenas-Morales G, et al. Autoantibodies to interferon-gamma in a patient with selective susceptibility to mycobacterial infection and organ-specific autoimmunity. Clin Infect Dis 2004;38:e10–4.
[19] Hoflich C, Sabat R, Rosseau S, et al. Naturally occurring anti-IFN-gamma autoantibody and severe infections with Mycobacterium chelonae and Burkholderia cocovenenans. Blood 2004;103:673–5.

[20] Kampmann B, Hemingway C, Stephens A, et al. Acquired predisposition to mycobacterial disease due to autoantibodies to IFN-gamma. J Clin Invest 2005;115:2480–8.

[21] Koya T, Tsubata C, Kagamu H, et al. Anti-interferon-gamma autoantibody in a patient with disseminated Mycobacterium avium complex. J Infect Chemother 2009;15:118–22.

[22] Browne SK, Burbelo PD, Chetchotisakd P, et al. Adult-onset immunodeficiency in Thailand and Taiwan. N Engl J Med 2012;367:725–34.

[23] Branger B, Gouby A, Oules R, et al. Mycobacterium haemophilum and mycobacterium xenopi associated infection in a renal transplant patient. Clin Nephrol 1985;23:46–9.

[24] Abbott MR, Smith DD. The pathogenic effects of Mycobacterium haemophilum in immunosuppressed albino mice. J Med Microbiol 1980;13:535–40.

[25] Wongkitisophon P, Rattanakaemakorn P, Tanrattanakorn S, et al. Cutaneous Mycobacterium abscessus infection associated with mesotherapy injection. Case Rep Dermatol 2011;3:37–41.

[26] Casumano LR, Tran V, Tlamsa A, et al. Rapidly growing Mycobacterium infections after cosmetic surgery in medical tourists: the Bronx experience and a review of the literature. Int J Infect Dis 2017;63:1–6.

[27] Hypolite T, Grant-Kels JM, Chirch LM. Nontuberculous mycobacterial infections: a potential complication of cosmetic procedures. Int J Womens Dermatol 2015;1:31–4.

[28] Cai SS, Chopra K, Lifchez SD. Management of Mycobacterium abscessus infection after medical tourism in cosmetic surgery and a review of literature. Ann Plast Surg 2016;77:678–82.

[29] Johnson PD, Lavender CJ. Correlation between Buruli ulcer and vector-borne notifiable diseases, Victoria, Australia. Emerg Infect Dis 2009;15:614–5.

[30] Wallace JR, Mangas KM, Porter JL, et al. Mycobacterium ulcerans low infectious dose and mechanical transmission support insect bites and puncturing injuries in the spread of Buruli ulcer. PLoS Negl Trop Dis 2017;11:e0005553.

[31] Tuchinda C, Ptvavilai S, Sathapatayavongs B, et al. Sweet’s syndrome: a reaction to non-tuberculous mycobacterial infections. J Med Assoc Thai 2004;87:567–72.

[32] Hibiya K, Miyagi K, Tamayose M, et al. Do infections with disseminated Mycobacterium avium complex precede sweet’s syndrome? A case report and literature review. Int J Mycobacteriol 2017;6:336–43.

[33] Choohonkarn C, Chetchotisakd P, Jirarattanapochai K, et al. Sweet’s syndrome associated with non-tuberculous mycobacterial infection: a report of five cases. Br J Dermatol 1998;139:107–10.

[34] Kawakami T, Ohashi S, Kawa Y, et al. Elevated serum granulocyte colony-stimulating factor levels in patients with active phase of sweet syndrome and patients with active behcet disease: implication in neutrophil apoptosis dysfunction. Arch Dermatol 2004;140:570–4.

[35] Song HS, Kim SJ, Park TJ, et al. Immunohistochemical comparison of IL-36 and the IL-23/Th17 axis of generalized pustular psoriasis and acute generalized exanthematous pustulosis. Ann Dermatol 2016;28:451–6.

[36] Wallace RJr, Swenson JM, Silcox VA, et al. Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities. J Infect Dis 1985;152:500–14.

[37] Wallace RJr, Tanner D, Brennan PJ, et al. Clinical trial of clarithromycin for cutaneous (disseminated) infection due to Mycobacterium chelonae. Ann Intern Med 1993;119:482–6.